Search

for
Search:

GlossaryGlucagon-Like Peptide-1

hormone that regulates blood sugar and promotes fullness

Glucagon-Like Peptide-1 (GLP-1) is a hormone produced in the gut that plays a crucial role in regulating blood sugar levels by enhancing insulin secretion and inhibiting glucagon release after eating. It also slows gastric emptying and promotes a feeling of fullness, making it a target for treatments in type 2 diabetes and obesity.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 231 results

research Glucagon-Like Peptide-1 Receptor and Proglucagon Expression in Mouse Skin

37 citations, March 2006 in “Regulatory Peptides”

Mice skin has components that could help with hair growth and might be used for diabetes treatment.

Risk of Suicide, Hair Loss, and Aspiration with Glucagon-Like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS Database

research Risk of Suicide, Hair Loss, and Aspiration with Glucagon-Like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS Database

November 2024 in “Circulation”

GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.

A 12-Week Treatment with the Long-Acting Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Leads to Significant Weight Loss in a Subset of Obese Women with Newly Diagnosed Polycystic Ovary Syndrome

research A 12-Week Treatment with the Long-Acting Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Leads to Significant Weight Loss in a Subset of Obese Women with Newly Diagnosed Polycystic Ovary Syndrome

61 citations, January 2015 in “Hormones”

Liraglutide caused significant weight loss in some obese women with PCOS, especially those with severe obesity and insulin resistance.

research GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

59 citations, August 2021 in “Frontiers in Endocrinology”

GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.

research Cardiovascular Profile of Pharmacological Agents Used for the Management of Polycystic Ovary Syndrome

4 citations, January 2019 in “Therapeutic Advances in Endocrinology and Metabolism”

Medications for PCOS don't seem to raise heart disease risk.

View more "glucagon-like peptide-1" in research →

Community Join

1 / 1 results

community Gyno & testoterone level

in Finasteride 282 upvotes 6 months ago

Switching from finasteride to dutasteride and back to finasteride led to gynecomastia and fatigue, likely due to hormonal imbalances. Suggested treatments include Tamoxifen, Raloxifene, or low-dose Anastrozole, with a recommendation to test testosterone and estradiol levels.